• Explore /
  • Poster
  • / Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).

Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).

Abstract Poster

Authors

null

James Yuhtyng Chen

Stanford University School of Medicine, Stanford, CA

James Yuhtyng Chen , Lisa Johnson , Kelly Marie McKenna , Timothy S. Choi , Jiaqi Duan , Dongdong Feng , Jonathan M. Tsai , Natalia Garcia-Martin , Kavitha Sompalli , Roy Maute , Paresh Vyas , Ravindra Majeti , Chris H.M. Takimoto , Jie Liu , Giridharan Ramsingh , Mark Chao , Jens-Peter Volkmer , Irving L. Weissman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT03248479

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7054)

DOI

10.1200/JCO.2022.40.16_suppl.7054

Abstract #

7054

Poster Bd #

285

Abstract Disclosures

Similar Posters

First Author: David Andrew Sallman

First Author: David Andrew Sallman

First Author: Naval Guastad Daver

First Author: Adrienne Sallets